Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q
Published on June 8, 2016 at 5:25 pm
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has said that it will file a new drug application (NDA) for its pipeline candidate brigatinib in 3Q2016. This followed a presentation of pivotal Phase 2 data for the compound at the ASCO conference. According to Ariad, brigatinib showed impressive results in ALK+ lung cancer patients who received it during the study. Those patients had experienced a progression of their disease condition even after receiving Pfizer Inc. (NYSE:PFE) drug Xalkori.
Ariad said that it has already initiated a Phase 3 study of brigatinib that will focus primarily on evaluating the efficacy of the compound against Xalkori from Pfizer.